Viking Therapeutics, Inc. (VKTX)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
37.97 USD
-0.15
(-0.393%) ⇩
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:08 a.m. EDT
The investment case here is a classic biotech gamble: extraordinary potential upside masked by severe fundamental risks. The company sits on a fortress-like balance sheet with over $600 million in cash and a current ratio of 5.7, providing ample runway to execute its obesity drug pipeline without immediate dilution fears. However, the fundamentals are currently broken; the stock trades at a negative forward P/E with negative ROE and free cash flow, reflecting the reality that it is still a pre-revenue entity burning cash. The recent price action shows a recovery from a 47% annual decline, yet the stock remains significantly below its 2024 highs, suggesting the market is still pricing in execution risk. The short-term outlook is bullish due to the confluence of insider buying and aggressive options positioning. The 'double top' pattern mentioned in recent commentary is being challenged by fresh capital, and the heavy options flow at the $50 strike acts as a magnet for volatility. If the upcoming clinical data validates the drug's superiority over Novo Nordisk rivals, the catalyst could trigger a rapid re-rating toward the $125 analyst target. Conversely, any stumble in the trials will leave the stock vulnerable given its lack of commercial revenue. For now, the risk/reward leans slightly toward the upside, but investors must treat this as a high-volatility event play rather than a stable compounder. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.079880 |
| AutoTheta | 0.081951 |
| MSTL | 0.086553 |
| AutoARIMA | 0.102970 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 4.43 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.012 |
| Excess Kurtosis | 0.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 4,408,531,456 |
| Forward P/E | -8.32 |
| Beta | 0.66 |
| Website | https://www.vikingtherapeutics.com |
As of July 11, 2026, 3:08 a.m. EDT: Speculators are positioning for a volatile breakout above $50, evidenced by massive open interest walls at the $50 strike for both calls and puts across multiple expirations. While there is significant hedging activity near current prices ($35-$40), the sheer volume of out-of-the-money contracts suggests a binary event-driven thesis, likely tied to upcoming Phase 3 trial results or regulatory milestones, rather than a steady grind higher.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.24169385 |
| Address1 | 9,920 Pacific Heights Boulevard |
| Address2 | Suite 350 |
| All Time High | 99.41 |
| All Time Low | 0.88 |
| Ask | 40.51 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 2,730,090 |
| Average Daily Volume3 Month | 2,441,714 |
| Average Volume | 2,441,714 |
| Average Volume10Days | 2,730,090 |
| Beta | 0.655 |
| Bid | 35.94 |
| Bid Size | 1 |
| Board Risk | 9 |
| Book Value | 5.567 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 37.97 |
| Current Ratio | 5.72 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 38.56 |
| Day Low | 37.2505 |
| Display Name | Viking Therapeutics |
| Earnings Call Timestamp End | 1,777,494,600 |
| Earnings Call Timestamp Start | 1,777,494,600 |
| Earnings Timestamp | 1,777,492,800 |
| Earnings Timestamp End | 1,785,355,200 |
| Earnings Timestamp Start | 1,785,355,200 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 3,805,567,232 |
| Eps Current Year | -4.72478 |
| Eps Forward | -4.56533 |
| Eps Trailing Twelve Months | -4.15 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 32.7154 |
| Fifty Day Average Change | 5.2546005 |
| Fifty Day Average Change Percent | 0.1606155 |
| Fifty Two Week Change Percent | 24.169386 |
| Fifty Two Week High | 43.15 |
| Fifty Two Week High Change | -5.1800003 |
| Fifty Two Week High Change Percent | -0.120046355 |
| Fifty Two Week Low | 22.959 |
| Fifty Two Week Low Change | 15.011002 |
| Fifty Two Week Low Change Percent | 0.6538178 |
| Fifty Two Week Range | 22.959 - 43.15 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,430,227,800,000 |
| Float Shares | 113,280,793 |
| Forward Eps | -4.56533 |
| Forward P E | -8.317033 |
| Free Cashflow | -177,354,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 59 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02786 |
| Held Percent Institutions | 0.64469004 |
| Implied Shares Outstanding | 116,105,643 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. |
| Long Name | Viking Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 4,408,531,456 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_246791410 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -472,335,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,425,947,111 |
| Number Of Analyst Opinions | 19 |
| Open | 37.91 |
| Operating Cashflow | -340,329,984 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 858 704 4660 |
| Pre Market Change | 0.02999878 |
| Pre Market Change Percent | 0.07900653 |
| Pre Market Price | 38.0 |
| Pre Market Time | 1,784,112,295 |
| Previous Close | 38.120003 |
| Price Eps Current Year | -8.036353 |
| Price Hint | 2 |
| Price To Book | 6.82055 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.671 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.45 |
| Region | US |
| Regular Market Change | -0.15000153 |
| Regular Market Change Percent | -0.3934982 |
| Regular Market Day High | 38.56 |
| Regular Market Day Low | 37.2505 |
| Regular Market Day Range | 37.2505 - 38.56 |
| Regular Market Open | 37.91 |
| Regular Market Previous Close | 38.120003 |
| Regular Market Price | 37.97 |
| Regular Market Time | 1,784,059,200 |
| Regular Market Volume | 1,341,034 |
| Return On Assets | -0.42535 |
| Return On Equity | -0.70036006 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 116,105,643 |
| Shares Percent Shares Out | 0.2025 |
| Shares Short | 23,507,768 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 22,371,620 |
| Short Name | Viking Therapeutics, Inc. |
| Short Percent Of Float | 0.214 |
| Short Ratio | 8.48 |
| Source Interval | 15 |
| State | CA |
| Symbol | VKTX |
| Target High Price | 125.0 |
| Target Low Price | 34.0 |
| Target Mean Price | 92.57895 |
| Target Median Price | 95.0 |
| Total Cash | 602,963,968 |
| Total Cash Per Share | 5.193 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.15 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 33.370975 |
| Two Hundred Day Average Change | 4.5990257 |
| Two Hundred Day Average Change Percent | 0.13781515 |
| Type Disp | Equity |
| Volume | 1,341,034 |
| Website | https://www.vikingtherapeutics.com |
| Zip | 92,121 |